Structure-anti-leukemic activity relationship study of B- and D-ring modified and non-modified steroidal esters of chlorambucil

Anti-Cancer Drugs

Volumn 17, Issue 5, 2006, Pages 511-519

  Fousteris, Manolis A ^a,d   Koutsourea, Anna I ^a   Arsenou, Evaggelia S ^a   Papageorgiou, Athanasios ^b   Mourelatos, Dionysios ^c   Nikolaropoulos, Sotiris S ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b Theagenion Anticancer Institute   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d UNIVERSITY OF PATRAS   (Greece)

Author keywords

Anti leukemic activity; B steroidal lactams; Chlorambucil; D steroidal lactams; Steroidal esters; Structure activity relationship

Indexed keywords

3BETA HYDROXY 17ALPHA AZA D HOMOANDROST 5 EN 17 ONE; 3BETA HYDROXY 17ALPHA AZA D HOMOANDROST 5 EN 7,17 DIONE; 3BETA HYDROXY 7A AZA B HOMOANDROST 5 EN 7,17 DIONE; 3BETA HYDROXY 7A,17A DIAZA B,D DIHOMOANDROST 5 EN 7,17 DIONE; 3BETA HYDROXYANDROST 5 EN 7,17 DIONE; ANTILEUKEMIC AGENT; CHLORAMBUCIL DERIVATIVE; FUNCTIONAL GROUP; PRASTERONE; STEROID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; LACTAMIZATION; LEUKEMIA L 1210; LEUKEMIA P 388; LYMPHOCYTE; MALE; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPECTROSCOPY; STRUCTURE ACTIVITY RELATION;

EID: 33748167455     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200606000-00004     Document Type: Article

References (46)

1. Kohn K. Beyond DNA cross-linking: history and prospects of DNA-targeted cancer treatment. Fifteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 1996; 56:5533-5546.
2. Ross WE, Ewig RA, Kohn KW. Differences between melphalan and nitrogen mustard in the formation and removal of DNA cross-links. Cancer Res 1978; 38:1502-1506.
3. Zwelling L, Michaels S, Schwartz H, Dobson PP, Kohn KW. DNA crosslinking as an indicator of sensitivity and resistance of L1210 leukemia cells to cis-diaminedichloroplatinum(II) and L-phenylalanine mustard. Cancer Res 1981; 41:640-649.
4. Brookes P, Lawley PD. The reaction of mono- and di-fuctional alkylating agents with nucleic acids. Biochem J 1961; 80:496-503.
5. Dusenbery KE, Bellairs EE, Potish RA, Twiggs LB, Boente MP. Twenty-five year outcome of sequential abdominal radiotherapy and melphalan: implications for future management of epithelial carcinoma of the ovary. Gynecol Oncol 2005; 96:307-313.
6. Shamash J, Dancey G, Barlow C, Wilson P, Ansell W, Oliver RT. Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding. Br J Cancer 2005; 92:36-40.
7. Brendel M, Ruhland A. Relationships between functionality and genetic toxicology of selected DNA-damaging agents. Mutat Res 1984; 133:51-85.
8. Morgan AS, Ciaccio PJ, Tew KD, Kauvar LM. Isozyme specific glutathione S-transferase inhibitors potentiate drug sensitivity in cultured human tumor cell lines. Cancer Chemother Pharmacol 1996; 37:363-370.
9. Green JA, Vistica DT, Young RC, Hamilton TC, Rogan AM, Ozols RF. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res 1984; 44:5427-5431.
10. Panasci L, Xu Z, Bello V, Aloyz R. The role of DNA repair in nitrogen mustard drug resistance. Anticancer Drugs 2002; 13:211-220.
11. Kaldor JM, Day NE, Hemminki K. Quantifying the carcinogenicity of antineoplasmatic drugs. Eur J Cancer Clin Oncol 1988; 24:703-711.
12. Denny WA. DNA minor groove alkylating agents. Curr Med Chem 2001; 8:533-543.
13. Bielawska A, Bielawski K, Chrzanowski K,Wotczynski S. Prolidase-activated prodrug for cancer chemotherapy, cytotoxic activity of proline analogue of chlorambucil in breast cancer. Farmaco 2000; 55:736-741.
14. Soyez H, Seymour LW, Schacht E. Macromolecular derivatives of N,N-di-(2-chloroethyl)-4-phenylene diamine mustard. 2. In vitro cytotoxicity and in vivo anticancer efficacy. J Control Release 1999; 57:187-196.
15. Kasiotis KM, Magiatis P, Pratsinis H, Skaltsounis AL, Abadji V, Charalambous A, et al. Synthesis and biological evaluation of novel daunorubicin-estrogen conjugates. Steroids 2001; 66:785-791.
16. Ferguson LR, Turner PM, Denny WA. The mutagenic spectrum of acridine-linked aniline nitrogen mustards in AS52 cells: implications of DNA targeting with high selectivity for adenine or guanine bases. Mutat Res 2000; 469:115-126.
17. Wasan H, Waxman J. In: Pusztai LL, Lewis CE, Yap E (editors): Cell proliferation cancer. Oxford: Oxford University Press; 1996. pp. 260-281.
18. Lupulescu AP. Hormones, vitamins, and growth factors in cancer treatment and prevention. A critical appraisal. Cancer 1996; 78:2264-2280.
19. Albrecht W, Van Poppel H, Horenlas S, Mickisch G, Horwich A, Secretta V, et al. Randomized phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer. Br J Cancer 2004; 90:100-105.
20. Brandt L, Konyves I, Moller TR. Therapeutic effect of LEO 1031, an alkylating corticosteroid ester, in lymphoproliferative disorders. I. Chronic lymphocytic leukemia. Acta Med Scand 1975; 197:317-322.
21. Nikolaropoulos S, Tsavdaridis D, Arsenou E, Papageorgiou A, Karaberis E, Mourelatos D. Synergistic antineoplastic and cytogenetic effects by the combined action of two homo-aza-steroidal esters of nitrogen mustards on P388 and L1210 leukaemias in vivo and in vitro. Anticancer Res 2000; 20:2745-2752.
22. Nikolaropoulos SS, Arsenou ES, Papageorgiou A, Mourelatos D. Antitumor and cytogenetic effects of esteric (ASE) and amidic (ASA) steroidal derivatives of p-bis(2-chloroethyl)amino phenylacetic acid (CAPA). A comparative study. Anticancer Res 1997; 17:4525-4530.
23. Anastasiou A, Catsoulacos P, Papageorgiou A, Margariti E. On the formation of homo-azasteroidal esters of N,N-bis(2-chloroethyl)aminobenzoic acid isomers and their antitumor activity. J Heterocycl Chem 1994; 31:367-373.
24. Athanasiou K, Demopoulos N, Catsoulacos P. Chromosome damage and SCE induced by the cytostatic factor homo-aza-steroidal ester of p-bis(2-chloroethyl) aminophenyl acetic acid in CHO cells in culture. Environ Mutagen 1983; 5:279-283.
25. Wall ME, Abernethy Jr GS, Caroll FJ, Taylor DJ. The effect of some steroidal alkylating agents on experimental animal mammary tumor and leukemia systems. J Med Chem 1969; 12:810-818.
26. Catsoulacos P, Politis D,Wampler GL. A new steroidal alkylating agent with improved activity in advanced murine leukemias. Cancer Chemother Pharmacol. 1979; 3:67-70.
27. Catsoulacos P,Wampler GL. Activity of 3bβ-hydroxy-13α-amino- 13,17-seco-5α-androstan-17-oic-13,17-lactam-p-bis(2-chloroethyl) -aminophenylacetate. Oncology 1982; 39:109-112.
28. Karayianni V, Papageorgiou A, Mioglou E, Iakovidou Z, Mourelatos D, Fousteris M, et al. 7-Keto hybrid steroidal esters of nitrogen mustard: cytogenetic and antineoplastic effects. Anticancer Drugs 2002; 13:637-643.
29. Arsenou E, Fousteris M, Koutsourea A, Papageorgiou A, Karayianni V, Mioglou E, et al. The allylic 7-ketone at the steroidal skeleton is crucial for the anti-leukemic potency of chlorambucil's active metabolite steroidal esters. Anticancer Drugs. 2004; 15:983-990.
30. Papageorgiou A, Koutsourea A, Arsenou E, Fousteris E, Mourelatos D, Nikolaropoulos S. Structure-anti-leukemic activity relationship study of B and D-ring modified and non-modified steroidal esters of chlorambucil's active metabolite. Anticancer Drugs 2005; 16:1075-1082.
31. McLean A, Woods RC, Catovsky D, Farmer P. Pharmacokinetics and metabolism of chlorambucil in patients with malignant disease. Cancer Treat Rev 1979; 6(Suppl):33-42.
32. Pettersson-Fernholm T, Vilpo J, Kosonen M, Hakala K, Hovinen J. Reactions of 4-bis(2-chloroethyl)aminophenylacetic acid (phenylacetic mustard) in physiological solutions. J Chem Soc Perkin Trans 2 1999; 2183-2187.
33. Pairas G, Camoutsis Ch, Catsoulacos P. A new route for the synthesis of steroidal esters of carboxylic derivatives of N,N-bis(2-chloroethyl)aniline with DCC. Eur J Med Chem Chim Ther 1985; 20:287-288.
34. Catsoulacos P, Boutis L. Cytostatic action of 3β-hydroxy-13α- amino-13,17-seco-5-androsten-17-oic-13,17-lactam-p-N,N-bis(2-chloroethyl) aminophenylacetate. Eur J Med Chem Chim Ther 1974; 9:211-213.
35. Regan BM, Hayes FN. 17 and 17α-aza-D-homo steroids. J Am Chem Soc 1956; 78:639-643.
36. 5- steroidal substrates. Steroids 2003; 68:407-414.
37. Koutsourea A, Arsenou E, Fousteris M, Nikolaropoulos S. Synthetic approaches for the synthesis of a cytostatic steroidal B-D bilactam. Steroids 2003; 68:659-666.
38. Strazzolini P, Giumanini G, Runcio A, Scuccato M. Experiments on the Chaperon effect in the nitration of aromatics. J Org Chem 1998; 63:952-958.
39. Goto K, Maeda S, Kano Y, Sugiyama T. Factors involved in differential Giemsa-staining of sister chromatids. Chromosoma 1978; 66:351-359.
40. Goldin A, Sofina Z, Syrkin A. Experimental evaluation of antitumor drugs in the USA and USSR and clinical correlations. Natl Cancer Inst Monogr 1980; 55:25-26.
41. Fousteris MA, Koutsourea AI, Arsenou ES, Papageorgiou A, Mourelatos D, Nikolaropoulos S. Antileukemic and cytogenetic effects of modified and non-modified esteric steroidal derivatives of 4-methyl-3-bis (2-chloroethyl)amino benzoic acid (4-Me-CABA). Anticancer Res 2002; 22:2293-2300.
42. Kasal A. Epalons: 6-substituted derivatives of 7-norepiallopregnanolone. Tetrahedron 2000; 56:3559-3565.
43. Deen DF, Kendall LA, Marton LJ, Tofilon P. Prediction of human tumour cell chemosensitivity using the SCE assay. Cancer Res 1986; 46:1599-1602.
44. Mourelatos D, Chromosomes study as predictor of chemoresponse of tumours. Cancer J 1996; 9:136-141.
45. Tolifon P, Basic I, Milas L. Prediction of in vivo tumor response to chemotherapeutic agents by the in vitro SCE assay. Cancer Res 1985; 45:2025-2030.
46. Mourelatos D, Dozi J, Kotsis A, Gourtsas C. Enhancement of cytogenetic damage and of antineoplastic effect by caffeine in Ehrlich ascites tumour cells treated with cyclophosphamide in vivo. Cancer Res 1988; 48:1129-1131.